Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

6 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Measurement Instrument Database for the Social Science (MIDSS) - The Functional Behavior Profile (FBP)

- 4/9/20 - 1 formulario, 1 itemgroup, 27 items, 1 idioma
Itemgroup: The Functional Behavior Profile
Baum, C., Edwards, D.F., Morrow-Howell, N. (1993). The Functional Behavior Profile (FBP). Measurement Instrument Database for the Social Science. Retrieved 04.09.2020, from www.midss.ie Key references: Baum, C Edwards, D.F. Morrow-Howell, N. (1993). Identification and measurement of productive behaviours in senile dementia of the Alzheimer type. The Gerontologist, 33, 403-408. Baum, M. C. and Edwards, D. F. (2000). Documenting productive behaviors. Using the functional behavior profile to plan discharge following stroke. J Gerontol Nurs, 26, 34-40; quiz 41-33. Burgener, S., Twigg, P., et al. (2005). "Measuring psychological well-being in cognitively impaired persons." Dementia 4(4): 463. Goverover, Y., Kalmar, J., et al. (2005). "The relation between subjective and objective measures of everyday life activities in persons with multiple sclerosis." Arch Phys Med Rehabil 86(12): 2303-2308. Primary use / Purpose: The Functional Behavior Profile (FBP) is a clinical assessment measure used to inform placement and discharge planning decisions following stroke. The FBP provides caregivers with a method of describing the impaired person’s capabilities in performing tasks, social interactions, and problem-solving. It was developed to guide treatment planning, documenting change, and identifying helpful community resources. Background: The Functional Behavior Profile (FBP) comprises 27 items concerning performance of daily activities by the cognitively impaired individual. The items are sectioned into three areas: Task Performance, Problem Solving, and Social Interaction. Each item is rated from 0 (never) to 4 (always) according to the subject’s behavior over the past 7 days. The checklist may be completed by the therapist by interviewing the primary caregiver or by the caregiver independently. Administration of the test takes, on average, 15 minutes. The FBP yields three scores for the factors of Task Performance, Problem Solving, and Social Interaction. An institutional version of the profile is also available for residents of facilities. Psychometrics: Internal consistency and criterion validity scores are provided in Baum et al. (2000) and Baum et al. (1993), respectively. Digital Object Identifier (DOI): http://dx.doi.org/10.13072/midss.258 The FBP is designed to obtain from the primary caregiver the overall capacity for their loved one to engage in tasks, social interactions and problem solving. All of the questions relate to how their loved one performs in their daily activities. As a reference, the caregiver should respond based upon the person's behavior during the past week. (It can be administered in interview or self scored format). Scoring: Total those marked according to the following key. You can use the task performance, social interaction, and problem solving scales separately or use a total score. Key: T: score items 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 P: score items 9, 10, 21, 22, 23, 24, 25, 26, 27 S: score items 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21

Rotterdem Symptom Checklist (RSCL) Week 36 Mepolizumab HES NCT00086658 - Rotterdem Symptom Checklist (RSCL) Week 36

- 15/7/17 - 1 formulario, 1 itemgroup, 2 items, 1 idioma
Itemgroup: Symptom checklist
Study part: Rotterdem Symptom Checklist (RSCL) Week 36/ Early Withdrawal Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Rotterdem Symptom Checklist (RSCL) Week 38 Mepolizumab HES NCT00086658 - Rotterdem Symptom Checklist (RSCL) Week 38

- 5/6/17 - 1 formulario, 1 itemgroup, 2 items, 1 idioma
Itemgroup: Symptom checklist
Study part: Rotterdem Symptom Checklist (RSCL) Week 38.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Rotterdem Symptom Checklist (RSCL) Week 12 Mepolizumab HES NCT00086658 - Rotterdem Symptom Checklist (RSCL) Week 12

- 5/6/17 - 1 formulario, 1 itemgroup, 2 items, 1 idioma
Itemgroup: Symptom checklist
Study part: Rotterdem Symptom Checklist (RSCL) Week 12.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Rotterdem Symptom Checklist (RSCL) Week 24 Mepolizumab HES NCT00086658 - Rotterdem Symptom Checklist (RSCL) Week 24

- 5/6/17 - 1 formulario, 1 itemgroup, 2 items, 1 idioma
Itemgroup: Symptom checklist
Study part: Rotterdem Symptom Checklist (RSCL) Week 24.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Rotterdem Symptom Checklist (RSCL) Day 1 Pre-Infusion Mepolizumab HES NCT00086658 - Rotterdem Symptom Checklist (RSCL) Day 1 Pre-Infusion

- 5/6/17 - 1 formulario, 1 itemgroup, 2 items, 1 idioma
Itemgroup: Symptom checklist
Study part: Rotterdem Symptom Checklist (RSCL) Day 1 Pre-Infusion.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial